SIREN : 442125274
CLINIQUE DEVELOPPEMENT is a French company founded 23 years ago, specialized in the sector Activités des sociétés holding. Based in VERTOU (44120), this company of category GE shows in 2024 a revenue of 3.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 842 189 € | 3 649 764 € | 3 608 847 € | 3 174 139 € | 4 058 264 € | 4 189 583 € | 4 105 937 € | 1 678 391 € | 1 471 429 € |
| Net income | 2 362 750 € | 2 940 182 € | 279 521 € | 5 033 390 € | 4 564 251 € | 3 752 169 € | 4 430 073 € | 4 246 € | 4 202 141 € |
| EBITDA | 3 526 406 € | 3 148 280 € | 3 001 871 € | 2 696 336 € | 2 642 489 € | 2 643 453 € | 2 569 120 € | -27 306 € | 589 740 € |
| Net margin | 61.5% | 80.6% | 7.7% | 158.6% | 112.5% | 89.6% | 107.9% | 0.3% | 285.6% |
In 2024, CLINIQUE DEVELOPPEMENT achieves revenue of 3.8 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +12.7%. Vs 2023: +5%. After deducting consumption (0 €), gross margin stands at 3.8 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.5 M€, representing 91.8% of revenue. Positive scissor effect: EBITDA margin improves by +5.5 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.4 M€, i.e. 61.5% of revenue. This profit can be retained or distributed to shareholders.
3 842 189 €
3 842 189 €
3 526 406 €
1 292 511 €
2 362 750 €
91.8%
The debt ratio (= Financial debt / Equity x 100) stands at 20%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 83%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.4 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 119.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
19.613%
83.254%
119.636%
2.431
52.6%
In 2024, the debt ratio of CLINIQUE DEVELOPPEMENT (19.61) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of CLINIQUE DEVELOPPEMENT (83.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of CLINIQUE DEVELOPPEMENT (2.43) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 3937.91. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 11.5x. Operating income very largely covers interest expenses: high safety margin.
3937.906
11.46
In 2024, the liquidity ratio of CLINIQUE DEVELOPPEMENT (3937.91) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of CLINIQUE DEVELOPPEMENT (11.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 37 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 1190 days. Excellent situation: suppliers finance 1153 days of the operating cycle (retail model). Overall, WCR represents 1007 days of revenue, i.e. 10.8 M€ to permanently finance. Over 2016-2024, WCR increased by +1768%, requiring additional financing.
10 750 906 €
37 j
1190 j
0 j
1007 j
Based on 54 transactions of similar company sales
in 2024,
the value of CLINIQUE DEVELOPPEMENT is estimated at
9 895 142 €
(range 2 305 558€ - 19 029 805€).
With an EBITDA of 3 526 406€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CLINIQUE DEVELOPPEMENT with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of CLINIQUE DEVELOPPEMENT in 2024 is 3.8 M€.
Yes, CLINIQUE DEVELOPPEMENT generated a net profit of 2.4 M€ in 2024.
The headquarters of CLINIQUE DEVELOPPEMENT is located in VERTOU (44120), in the department Loire-Atlantique.
The tax return of CLINIQUE DEVELOPPEMENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CLINIQUE DEVELOPPEMENT operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.